Security
CONTRAVIR PHARMACEUTICALS INC Preferred Stock - Series C · CTRVP
CTRVPOTCPreferred stockCurrentCIK 1583771Updated Oct 28, 2026
Name history
ContraVir Pharmaceuticals, Inc. · through Jul 23, 2019
CTRVP price & chart
Loading TradingView…
OTC:CTRVP on TradingView ↗In the news
No coverage from other publishers is available.
SEC disclosures
Recent filings
4 filing
SCHEDULE 13G/A - filed by RICKEL KENNETH regarding Hepion Pharmaceuticals, Inc.
S-8 filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.01, 2.01, 3.02, 5.02, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Show 5 more recent filings
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
SCHEDULE 13D/A - filed by KI Holdings, Ltd. regarding Hepion Pharmaceuticals, Inc.
DEF 14C filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
PRE 14C filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 3,740,240Source | 3,715,098Source | 1,927,442Source | 4,505,469Source | 6,010,164Source | 2,705,503Source | 6,318,555Source | 15,989,411Source | 3,069,952Source | 1,613,737Source | 18,094,397Source | 60,244,452Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | 0Source | — | — | 29,487Source | 81,620Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Current assets: | ||||||||||||
| Assets, CurrentUSD | 3,740,240Source | 3,530,292Source | 1,927,442Source | 4,505,469Source | 5,482,409Source | 2,705,503Source | 6,318,555Source | 15,430,371Source | 3,069,952Source | 1,613,737Source | 17,487,840Source | 56,496,073Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 118,301Source | — | 0Source | 150,733Source | — | 0Source | 182,019Source | 0Source | — | 212,878Source | 50,585Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 415,808Source | 4,121,783Source | 648,923Source | 708,531Source | 2,448,334Source | 848,747Source | 2,422,492Source | 8,467,972Source | 402,405Source | 3,477,075Source | 10,813,590Source | 10,388,515Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,162Source | 663Source | 2,912Source | 1,162Source | 547Source | 1,162Source | 959Source | 547Source | 1,162Source | 14Source | 482Source | 7,623Source |
| Additional Paid in CapitalUSD | 247,060,568Source | — | 247,728,818Source | — | — | 247,060,568Source | — | — | 247,060,568Source | 234,252,981Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -245,440,771Source | -236,272,352Source | -248,156,684Source | -244,968,265Source | -231,406,404Source | -246,908,447Source | -243,925,693Source | -227,481,192Source | -246,097,656Source | -237,819,806Source | -224,627,386Source | -175,701,344Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 8,345Source | -53,831Source | 8,345Source | 8,345Source | -53,822Source | 8,345Source | 8,345Source | 9,200Source | 8,345Source | 8,345Source | -78,779Source | -90,168Source |
| Stockholders' Equity Attributable to ParentUSD | 3,324,432Source | 406,685Source | 1,278,519Source | 3,796,938Source | 3,561,830Source | 1,856,756Source | 3,896,063Source | 7,521,439Source | 2,667,547Source | -1,863,338Source | 7,280,807Source | 49,855,937Source |
| Additional Paid in Capital, Common StockUSD | — | 234,223,707Source | — | 247,060,568Source | 233,326,381Source | — | 246,117,324Source | 233,297,756Source | — | — | 230,291,362Source | 223,943,698Source |
| Liabilities and EquityUSD | 3,740,240Source | 3,715,098Source | 1,927,442Source | 4,505,469Source | 6,010,164Source | 2,705,503Source | 6,318,555Source | 15,989,411Source | 3,069,952Source | 1,613,737Source | 18,094,397Source | 60,244,452Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 347,411Source | 2,715,964Source | 492,759Source | 592,854Source | 975,634Source | 735,572Source | 935,924Source | 2,573,924Source | 299,383Source | 3,143,886Source | 5,290,096Source | 7,885,722Source |
| Operating Lease, Liability, CurrentUSD | — | 117,952Source | — | — | 154,090Source | — | — | 134,020Source | — | — | 115,916Source | 53,614Source |
| Accounts Payable, CurrentUSD | 77,243Source | 186,259Source | 169,875Source | 172,698Source | 446,544Source | 138,442Source | 243,259Source | 1,497,151Source | 167,810Source | 220,202Source | 2,348,829Source | 2,665,896Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | 41,248Source | — | — | 93,104Source | 0Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 409,022Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 55,859Source | 306,000Source | 322,884Source | 48,495Source | 375,000Source | 347,130Source | 166,487Source | 793,753Source | 77,507Source | 23,684Source | 2,439,351Source | 4,799,983Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 409,022Source |
| Prepaid Expense and Other Assets, Current | — | — | — | — | —Source | — | — | —Source | — | — | — | — |
| Other Assets, Noncurrent | — | —Source | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | — | 30,758Source | 67,131Source | 77,461Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 20,783Source | 20,783Source | 791,645Source | 1,340,311Source | 2,552,736Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 578,584Source | -1,117,422Source | -3,271,520Source | -18,216,303Source | -40,888,878Source | -34,961,171Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -132,117Source | -600,000Source | -14,304Source | -14,070Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 14,304Source | 16,336Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 195,934Source | 5,297,403Source | 4,825,291Source | 4,349,707Source | 4,494,950Source | -5,137,500Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 774,518Source | 4,179,981Source | 1,421,654Source | -14,379,472Source | -36,403,208Source | -40,159,879Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,321,078Source | 1,497,106Source | 1,628,625Source | 2,924,395Source | 2,602,580Source | 4,586,389Source | 1,828,062Source | 406,408Source | 14,785,880Source | 51,189,088Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 17,765Source | — | 0Source | 941Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | 87,124Source | 5,024Source | -47,138Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 28,625Source | — | — | — | 20,783Source | 20,783Source | 791,645Source | 2,416,915Source | 2,552,736Source |
| DepreciationUSD | — | — | — | 0Source | — | — | — | — | — | 100,000Source | 100,000Source | 100,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | 20,402Source | — | 0Source | — | 0Source | 100,000Source | 100,000Source | 100,000Source | 16,942Source |
| General and Administrative ExpenseUSD | — | — | 527,902Source | 1,695,550Source | 1,160,573Source | 919,488Source | 728,509Source | 1,258,360Source | 3,315,433Source | 7,499,230Source | 9,618,298Source | 10,348,465Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | — | — | 402,746Source | — | — | 402,746Source | — | 3,190,000Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 1,870,924Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 3,200,000Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | -2,969,252Source | -409,022Source | -2,883,849Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -472,506Source | -4,865,948Source | -1,248,237Source | -1,042,572Source | -810,791Source | -6,105,887Source | -8,277,850Source | -13,192,420Source | -48,926,042Source | -42,200,049Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -48,926,042Source | -45,337,549Source |
| Operating ExpensesUSD | — | — | 527,902Source | 4,458,259Source | 1,211,491Source | 1,745,511Source | 798,509Source | 1,280,595Source | 4,163,691Source | 19,346,578Source | 48,447,954Source | 45,488,726Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 200,000Source | 300,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 132,117Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 9,000,000Source | 9,000,000Source | 2,500,000Source | 4,494,950Source | 0Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | 100,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Operating Income (Loss)USD | — | — | -527,902Source | -4,458,259Source | -1,211,491Source | -1,745,511Source | -798,509Source | -1,280,595Source | -4,163,691Source | -19,346,578Source | -48,447,954Source | -45,488,726Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -472,506Source | -4,865,948Source | — | -1,042,572Source | — | -6,105,887Source | -8,277,850Source | -16,161,672Source | -49,335,064Source | -45,083,898Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | -2,969,252Source | -409,022Source | -2,883,849Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -472,506Source | -4,865,948Source | -1,248,237Source | -1,042,572Source | -810,791Source | -6,105,887Source | -8,277,850Source | -13,192,420Source | -48,926,042Source | -42,200,049Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.04Source | -36.21Source | -0.08Source | -0.09Source | -0.07Source | -2.15Source | -0.88Source | -107.35Source | -12.32Source | -0.59Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.04Source | -36.21Source | -0.08Source | -0.09Source | -0.07Source | -2.15Source | -0.88Source | -107.35Source | -12.32Source | -0.59Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 11,620,317Source | 134,379Source | 16,193,404Source | 11,328,122Source | 11,620,317Source | 2,836,700Source | 9,409,375Source | 122,894Source | 3,970,810Source | 76,229,440Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 11,620,317Source | 134,379Source | 16,193,404Source | 11,328,122Source | 11,620,317Source | 2,836,700Source | 9,409,375Source | 122,894Source | 3,970,810Source | 76,229,440Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | 20,402Source | — | 0Source | — | 0Source | 100,000Source | 100,000Source | 100,000Source | 16,942Source |
| General and Administrative ExpenseUSD | — | — | 527,902Source | 1,695,550Source | 1,160,573Source | 919,488Source | 728,509Source | 1,258,360Source | 3,315,433Source | 7,499,230Source | 9,618,298Source | 10,348,465Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 1,870,924Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 9,465Source | 10,164Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 8,116Source | -474,570Source | 6,243Source | 4,866Source | -2,129Source | -24,811Source | -24,406Source | -1,247,313Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -48,926,042Source | -45,337,549Source |
| Operating ExpensesUSD | — | — | 527,902Source | 4,458,259Source | 1,211,491Source | 1,745,511Source | 798,509Source | 1,280,595Source | 4,163,691Source | 19,346,578Source | 48,447,954Source | 45,488,726Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 200,000Source | 300,000Source |
| Research and Development ExpenseUSD | — | — | — | 2,762,709Source | 50,918Source | 423,277Source | 70,000Source | 22,235Source | 445,512Source | 11,847,348Source | 35,639,656Source | 33,269,337Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | 100,000Source | — | — |
Offerings
Registration 333-284052
- Gross proceeds
- 9000000.0
- Net proceeds
- 8280000.0
- Deal price
- 0.325
- Shares
- 27692308
- Offering price
- $0.325
- Ticker
- HEPA
Filing attachments
ex107.htm · S-8 · 2026-10-14
Calculation of Filing Fee Tables S-8 Hepion Pharmaceuticals, Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ────────────────────────────────────────────────…
Read attachment ↗ex4-1.htm · 8-K · 2026-09-08
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THIS NOTE AND SUCH SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION UNDER SUCH LAWS OR AN EXEM…
Read attachment ↗ex4-2.htm · 8-K · 2026-09-08
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex107.htm · S-8 · 2026-08-07
Calculation of Filing Fee Tables S-8 Hepion Pharmaceuticals, Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ───────────────────────────────────────────────…
Read attachment ↗ex4-1.htm · 8-K · 2026-08-04
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-03
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests under new leadership MORRISTOWN, N.J., March 3, 2026 - Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a …
Read attachment ↗